CD4 and systemic lupus erythematosus: In this context, our focus is on the evidence supporting the notion that metabolic modulators, aimed at improving the impaired CD4+ T cell metabolism in SLE, could serve as a therapeutic alternative in managing hypertension in SLE patients.